Seralutinib is a novel selective tyrosine kinase inhibitor that targets the PDGFRa/b, CSF1R, and c-kit pathways, which play a key role in the pathological inflammation and remodeling involved in PAH [66,67]. This evidence concerns the gene PDGFRA and pulmonary arterial hypertension.